Biocompatibility testing of medical plastics verifies that polymeric materials used in medical devices are safe for their intended patient-contact applications. Guided primarily by the ISO 10993 series of standards (adopted in China as the GB/T 16886 series), this evaluation combines in vitro assays, in vivo studies, and chemical characterization to identify potential cytotoxic, sensitizing, irritant, or systemic hazards. This article outlines the technical framework, sample requirements, core testing items, standard test methods, and typical applications of biocompatibility evaluation for medical-grade plastics.
Technical Overview
Medical plastics are polymeric materials such as PVC, polyethylene, polypropylene, polycarbonate, polyurethane, silicone elastomers, PEEK, polystyrene, and cyclic olefin copolymers used in devices ranging from syringes and catheters to implants and diagnostic consumables. Because these materials may release residual monomers, plasticizers, stabilizers, colorants, processing aids, sterilant residues, or degradation products into surrounding tissue, blood, or drug solutions, their biological safety must be demonstrated before market release.
The evaluation framework is defined by ISO 10993-1 (Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process), which is adopted in China as GB/T 16886.1 and complemented by ASTM, EN, and JIS standards. Test selection follows a risk-based matrix built on two parameters: the nature of body contact (surface devices, external communicating devices, and implant devices) and the contact duration (limited, up to 24 hours; prolonged, 24 hours to 30 days; permanent, more than 30 days).
Modern programs increasingly emphasize chemical characterization and toxicological risk assessment (ISO 10993-18 and ISO 10993-17) as a science-based alternative or supplement to animal testing. Testing is typically performed by accredited third-party laboratories under GLP or ISO/IEC 17025 quality systems, and the results are compiled into a biological evaluation report supporting regulatory submissions worldwide.
Testing Samples
Polymeric Resins and Compounds
Material-level testing is performed during supplier qualification and design selection on pellets, granules, or plaques of the base resin, including PVC compounds with alternative plasticizers, thermoplastic polyurethanes, silicone elastomers, polyolefins, engineering plastics, and masterbatches. Establishing a material biocompatibility database reduces duplicated testing for downstream devices, provided that composition and processing remain controlled.
Finished Device Components
Final evaluation should use devices or representative components in their finished, processed, and sterilized condition, for example catheter tubing, syringe barrels, plunger stoppers, luer connectors, filter membranes, housings, and blood-contacting surfaces. Molding parameters, adhesives, printing inks, cleaning agents, and sterilization methods such as ethylene oxide, gamma, electron beam, or steam can all alter the extractable profile relative to the raw resin.
Sample Preparation and Extraction
Sample preparation follows ISO 10993-12. Test articles are extracted at standardized surface-area-to-volume or mass-to-volume ratios in polar media (physiological saline, cell culture medium), non-polar media (sesame or cottonseed oil), and, where appropriate, intermediate-polarity media such as ethanol/water or ethanol/saline. Extraction conditions, for example 37 °C for 72 hours, 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour, are chosen to simulate or exaggerate clinical use without degrading the polymer.
Testing Items
The endpoints to be addressed for medical plastics are determined by the ISO 10993-1 selection matrix and typically include the following:
- Cytotoxicity — in vitro assessment of cell damage caused by extracts or direct material contact
- Sensitization — delayed-type hypersensitivity potential, a type IV immunological response
- Irritation and intracutaneous reactivity — local inflammatory response at the contact site
- Systemic toxicity — acute, subacute, and subchronic effects after single or repeated exposure to extracts
- Genotoxicity — gene mutation and chromosomal damage endpoints
- Hemocompatibility — hemolysis, thrombogenicity, complement activation, coagulation, and blood cell interactions for blood-contacting plastics
- Local effects after implantation — tissue response at the implant site for prolonged and permanent contact materials
- Pyrogenicity and bacterial endotoxins — fever-causing contaminants, particularly for intravascular and fluid-path devices
- Chemical characterization — extractables and leachables, residual monomers, additives, elemental impurities, and volatile organic compounds
- Degradation analysis — identification and quantification of degradation products for absorbable or biodegradable plastics (ISO 10993-9, -13, -14, and -15)
Testing Methods
In Vitro Cytotoxicity (ISO 10993-5)
The extract (elution) method exposes mammalian cells such as L929 mouse fibroblasts to material extracts for 24 to 48 hours, with viability quantified by MTT or neutral red uptake; direct-contact and agar-diffusion designs are alternatives for specific geometries. Cell viability below 70 percent of the blank control indicates a cytotoxic potential requiring follow-up analysis.
Sensitization and Irritation (ISO 10993-10, ISO 10993-23)
Sensitization is evaluated by the guinea pig maximization test, the Buehler test, or the non-animal local lymph node assay (LLNA). Irritation is assessed by intracutaneous reactivity testing in rabbits or by validated reconstructed human epidermis in vitro models, scored against the polar and non-polar extraction blanks.
Systemic Toxicity (ISO 10993-11)
Extracts are administered to mice or rats by intravenous or intraperitoneal injection for acute studies, or dosed repeatedly for 14 to 28 day subacute studies and up to 90 day subchronic studies. Endpoints include mortality, clinical signs, body weight, feed consumption, hematology, clinical chemistry, and gross and microscopic pathology.
Genotoxicity (ISO 10993-3)
A standard battery comprises the bacterial reverse mutation (Ames) test, an in vitro mammalian chromosomal aberration or mouse lymphoma assay, and, when warranted, an in vivo micronucleus test, performed on extracts with and without metabolic activation.
Hemocompatibility (ISO 10993-4)
Blood-contacting plastics undergo hemolysis testing by direct and indirect contact, with hemolysis rates generally required below 5 percent, together with complement activation (C3a/C5a), coagulation assays (PT, aPTT), platelet and leukocyte counts, and thrombogenicity assessment depending on the blood-contact category.
Implantation Studies (ISO 10993-6)
Material strips or finished sections are implanted intramuscularly or subcutaneously in rabbits or rodents for periods from 1 to 12 weeks or longer, matching the intended clinical exposure. Histopathological scoring compares the inflammatory, fibrotic, and degenerative response of the test material against a control material.
Chemical Characterization and Toxicological Risk Assessment (ISO 10993-18, ISO 10993-17)
Extracts are analyzed by GC-MS, LC-MS, headspace GC, ICP-MS, and FTIR to build an extractables profile under exaggerated and simulated-use conditions. Identified compounds are subjected to toxicological risk assessment using tolerable intake values, safety margin calculations, and thresholds of toxicological concern to justify waiving specific biological tests.
Applications
Biocompatibility testing of medical plastics supports product development, supplier qualification, and regulatory submission across the medical device industry:
- Infusion, transfusion, and injection devices — syringes, infusion and transfusion sets, IV catheters, stopcocks, and blood bags
- Extracorporeal circulation and renal care — hemodialyzer housings, blood tubing lines, oxygenator components, and apheresis consumables
- Implantable devices — PEEK spinal and orthopedic implants, silicone components, pacemaker and neurostimulator housings, and absorbable fixation devices
- Respiratory and anesthesia equipment — masks, breathing circuits, endotracheal tubes, and humidifier chambers
- Wound care and drug delivery — wound contact layers, transdermal system components, inhaler parts, and prefilled syringe barrels and plungers
- Diagnostics and laboratory consumables — microplates, pipette tips, cuvettes, and sample collection tubes where biological safety claims are required
- Sterile barrier and pharmaceutical packaging — thermoformed trays, blister lidding, and container-closure components for parenteral products
FAQ
Which standards govern biocompatibility testing of medical plastics?
The ISO 10993 series is the primary framework, adopted in China as GB/T 16886. Supporting references include ASTM material and extraction practices together with EN and JIS equivalents. Test selection is defined by ISO 10993-1, and sample preparation by ISO 10993-12.
How are the required tests selected for a specific plastic device?
Selection depends on the categorization of the device by body-contact type (surface, external communicating, or implant) and contact duration (limited, prolonged, or permanent), combined with a materials risk review. A PVC infusion set with prolonged blood contact requires cytotoxicity, sensitization, irritation, pyrogenicity, hemocompatibility, and chemical characterization, whereas a short-term skin-contact housing may need only cytotoxicity, sensitization, and irritation.
Can material-level test reports be reused for finished devices?
Partially. Resin-level data can support a biological evaluation, but the final device in its sterilized, finished state must be justified, because molding, assembly, adhesives, inks, cleaning, and sterilization can introduce new extractables. A gap analysis against ISO 10993-18 data is typically required.
What sample quantities are needed?
Requirements depend on the surface area or mass extraction ratios defined in ISO 10993-12. As a practical guideline, laboratories usually request finished devices or material sections corresponding to several hundred square centimeters of contact surface, or tens of grams of resin, per extraction solvent, plus retained samples and reference controls.
How long does a typical test program take?
In vitro cytotoxicity is generally completed within two to four weeks, sensitization within four to eight weeks, subacute systemic toxicity within two to three months, and implantation studies from three months up to one year for permanent-contact claims. Chemical characterization adds roughly six to twelve weeks including toxicological assessment.
Does ISO 10993 testing replace older pharmacopeial Class VI plastic tests?
No. Class VI-type tests (systemic injection, intracutaneous, and implantation screens) are short-term pass/fail screens, while the ISO 10993 series provides a risk-based, endpoint-driven evaluation aligned with current regulatory expectations. Some suppliers still provide both datasets for legacy compliance.